MK-571

• CAS Number:

  115104-28-4

• UNSPSC Description:

  MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].

• Target Antigen:

  Leukotriene Receptor; LPL Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/MK-571.html

• Purity:

  98.66

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(O)CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O

• Molecular Weight:

  515.09

• References & Citations:

  [1]Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D₄ receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28.|[2]Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97.|[3]Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9.Biomed Pharmacother. 2020 Sep;129:110506.|Cell Death Discov. 2024 Aug 14;10(1):364.|J Pharmaceut Biomed. 2020 Sep 10;189:113441.|Nat Commun. 2023 Sep 19;14(1):5709.|Viruses. 2019 Apr 24;11(4):378.|Arch Toxicol. 2020 Nov;94(11):3799-3817.|Biomed Pharmacother. 2018 Oct;106:1563-1569.|Brain Res Bull. 2022 Aug 15;S0361-9230(22)00199-X.|Cancer Res Commun. 2024 Apr 9;4(4):1024-1040.|Cell. 2023 Dec 7;186(25):5500-5516.e21.|CNS Neurosci Ther. 2022 Oct 17.|Commun Biol. 2024 May 23;7(1):621.|Eberhard Karls Universität Tübingen. 2022 Feb.|Eur J Drug Metab Pharmacokinet. 2022 Feb 3.|Eur J Drug Metab Pharmacokinet. 2024 Jul 4.|Eur J Pharm Sci. 2023 May 1.|Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8.|Int J Nanomedicine. 2019 Nov 27;14:9217-9234.|J Appl Toxicol. 2024 Jul 18.|Pharmaceutics. 2024 May 29.|Pharmacol Res Perspect. 2022 Feb;10(1):e00928.|Regul Toxicol Phar. 2019 Nov;108:104449. |Toxicol Lett. 2020 Jul 1;327:9-18.|Xenobiotica. 2020 Mar;50(3):354-362.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported